Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17
Massachusetts may be the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a psychedelic compound found in "magic mushrooms", worth paying attention to related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?
Compass Pathways Cuts 30% of Workforce on Phase 3 Trial Delays
Compass Pathways Is Maintained at Outperform by RBC Capital
Compass Pathways Analyst Ratings
